298 related articles for article (PubMed ID: 29043208)
1. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
Ghorbani-Aghbolaghi A; Darrow MA; Wang T
Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
[TBL] [Abstract][Full Text] [Related]
2. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
3. Hiding in plain sight: Gene panel and genetic markers reveal 26-year undiagnosed tumor-induced osteomalacia of the rib concurrently misdiagnosed as X-linked hypophosphatemia.
Colazo JM; DeCorte JA; Gillaspie EA; Folpe AL; Dahir KM
Bone Rep; 2021 Jun; 14():100744. PubMed ID: 33490314
[TBL] [Abstract][Full Text] [Related]
4. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced osteomalacia.
Florenzano P; Gafni RI; Collins MT
Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
[TBL] [Abstract][Full Text] [Related]
6. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
[TBL] [Abstract][Full Text] [Related]
7. Phosphaturic mesenchymal tumor with
Dwabe S; Chow W
Ther Adv Med Oncol; 2024; 16():17588359241232092. PubMed ID: 38455709
[TBL] [Abstract][Full Text] [Related]
8. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
9. Phosphaturic Mesenchymal Tumor in the Proximal Femur Presenting as Tumor-induced Osteomalacia: A Case Report and Literature Review.
Tungenwar S; Subith S; Mukadam M; Kokate S; Gunay S
J Orthop Case Rep; 2024 Feb; 14(2):23-28. PubMed ID: 38420233
[TBL] [Abstract][Full Text] [Related]
10. The phosphaturic mesenchymal tumor as a cause of oncogenic osteomalacia. Three cases and review of the literature.
Moreno Romero M; Pérez Muñoz I; González Lizán F; Gallego Rivera JI; Valdivielso Cañas L
Rev Esp Cir Ortop Traumatol (Engl Ed); 2021 Apr; ():. PubMed ID: 33903024
[TBL] [Abstract][Full Text] [Related]
11. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
Hartley IR; Roszko KL; Li X; Pozo K; Streit J; Del Rivero J; Magone MT; Smith MR; Vold R; Dambkowski CL; Collins MT; Gafni RI
JBMR Plus; 2022 Aug; 6(8):e10661. PubMed ID: 35991529
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor.
Sun L; Dehner C; Kenney J; McNulty SM; Zhu X; Pfeifer JD; Maluf HM; Chrisinger JSA
Virchows Arch; 2021 Apr; 478(4):757-765. PubMed ID: 33151412
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria.
Velazquez-Navarro JA; Loya-Teruel E; Rios-Gomez M; Montes-Ramirez JE
Cureus; 2022 Jan; 14(1):e20893. PubMed ID: 35145798
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced osteomalacia treated with T12 tumor resection.
Mancini AJ; Sabet A; Nielsen GP; Parker JA; Schwab JH; Ward A; Wu JS; Malabanan AO
Endocrinol Diabetes Metab Case Rep; 2022 Dec; 2022():. PubMed ID: 36511458
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.
Tajima S; Fukayama M
Int J Clin Exp Pathol; 2015; 8(8):9422-7. PubMed ID: 26464698
[TBL] [Abstract][Full Text] [Related]
16. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the "nonphosphaturic" variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization.
Sent-Doux KN; Mackinnon C; Lee JC; Folpe AL; Habeeb O
Hum Pathol; 2018 Oct; 80():94-98. PubMed ID: 29514106
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
Abate V; Vergatti A; De Filippo G; Damiano V; Menale C; D'Elia L; Rendina D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1006-e1011. PubMed ID: 38006315
[TBL] [Abstract][Full Text] [Related]
19. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors.
Carter JM; Caron BL; Dogan A; Folpe AL
Am J Surg Pathol; 2015 Jan; 39(1):75-83. PubMed ID: 25025444
[TBL] [Abstract][Full Text] [Related]
20. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
Higley M; Beckett B; Schmahmann S; Dacey E; Foss E
Skeletal Radiol; 2015 Dec; 44(12):1825-31. PubMed ID: 26341245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]